Biopharmaceutical firms in the U.S. and Europe are turning to China’s biotech sector for new medicines, with licensing ...

The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to ...

The asset deal thrusts AbbVie to the forefront of the psychedelic field, handing it a therapy that recently scored positive ...

The St. Louis-based biotech hopes to submit an application for its leukemia and lymphoma therapy in 2027, if all goes well in ...

Faster review times could leave drugmakers vulnerable to litigation, while new Trump administration priorities add more ...

An $885M deal with BeOne Medicine gives the pharma financier rights to a revenue stream from global sales of Imdelltra, which ...

A federal register notice confirmed dates for the anticipated advisory meeting, which will follow an FDA decision to narrow COVID boosters' approval and comes as CDC leadership is in turmoil.

Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly ...

The company’s market value was nearly cut in half following trial results showing higher rates of treatment discontinuations ...

The agreement provides research funding for Replicate and up to $550M in payments to develop medicines for diseases including obesity and diabetes.

AMX0035 missed the goals of a study in progressive supranuclear palsy. Elsewhere, Novartis and BioArctic struck a deal, and Genentech started building its first East Coast factory.

While the agency cleared vaccines from Pfizer, Moderna and Novavax broadly in older adults, it restricted eligibility in ...